查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992475

兽药市场：2026年至2032年全球市场预测（依药物类型、目标动物、剂型、给药途径、製剂类型、通路、治疗领域及最终用户划分）

Animal Drug Compounding Market by Drug Type, Animal Type, Form, Route Of Administration, Compounding Type, Distribution Channel, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物药品市场价值将达到 14.5 亿美元，到 2026 年将成长到 15.7 亿美元，到 2032 年将达到 25.1 亿美元，复合年增长率为 8.10%。

主要市场统计数据
基准年 2025 14.5亿美元
预计年份：2026年 15.7亿美元
预测年份 2032 25.1亿美元
复合年增长率 (%) 8.10%

关于动物製剂在兽医和农业健康中的战略作用、范围和实际目标的权威框架。

本执行摘要首先概述了动物製剂在现代兽医学和农业管理中的战略必要性。製剂的出现拓展了兽医和动物保健专业人员的治疗选择，使其能够实现剂量定制、为小型或易感动物提供替代配方，以及在核准的产品缺货时提供定製配方。因此，製剂有助于改善急性和慢性疾病的临床疗效，提高伴侣动物的用药依从性，并为特殊畜牧业的干预措施提供针对性解决方案。

监管力道加大、供应链波动以及临床上对个人化治疗方法的需求，是如何改变药品分发操作和品管系统的？

近年来，动物用药品产业经历了与监管、临床实践和供应链趋势相关的多项变革性变化。法律规范提高了全球对无菌性、标籤和批号记录的标准，迫使药剂师加强品质系统建设并增加对环境监测项目的投入。同时，临床实践也在不断发展，兽医越来越依赖定製配方来应对诸如慢性病管理、老年动物护理以及市售产品无法满足的物种特异性剂量等挑战。

2025 年美国关税调整对整个药局业务的采购、配方验证和定价趋势的营运和采购影响。

2025年美国实施或调整的关税政策和贸易措施对药房生态系统产生了重大营运影响，尤其对活性成分、添加剂、包装材料和专用设备的进口影响显着。某些化学品和成品关税的增加往往会对全球采购的原材料造成成本压力，促使采购团队重新评估其供应商组合和总到岸成本。对于规模小规模、难以承受原料价格剧烈波动的药局和诊所而言，这些影响更为显着。

一个详细的细分框架，将药物类别、特异性疾病需求、製剂类型、给药途径、分销管道和最终用户概况与营运重点联繫起来。

透过详细的细分观点，可以揭示临床需求、製剂能力和分销管道的重迭领域，从而突出目标机会和营运挑战。根据药物类型，分销需求涵盖抗感染药物、抗发炎药物、中枢神经系统 (CNS) 药物、荷尔蒙及其替代品，每种药物在稳定性、辅料和无菌性方面都有其独特的考量。例如，荷尔蒙製剂需要特殊的处理和低温运输要求，而中枢神经系统药物通常需要精确的剂量调整和对副作用的密切监测。

美洲、欧洲、中东和非洲以及亚太地区的区域监管差异、供应链角色和实施模式如何影响分销策略和营运风险？

区域趋势持续影响整个製药业的监管预期、筹资策略和应用模式。在美洲，法律规范强调可追溯性、无菌保证和配药记录的透明度，而商业性应用则受到服务于伴侣动物和大规模畜牧养殖场的兽医院和专科药房组成的密集生态系统的影响。这种区域结构既有利于快速的临床回馈循环，也有利于集中监管配药操作和文件记录。

药局供应商的策略重点和营运差异化因素，重点在于优质基础设施、临床整合和有韧性的供应链。

动物用药品分送产业的企业正着力应对多项策略挑战，这些挑战决定了它们的绩效和韧性。领先的药房和服务供应商优先投资于高品质的基础设施，包括经过验证的无尘室、环境监测系统和严格的无菌检测通讯协定，以满足日益增长的监管要求，并拓展注射剂和生物製药等相关製剂的业务。除了设施升级外，各企业还在透过标准化批次记录、电子追溯和定期第三方审核来制定合规计画。

医药产业的领导者们正在采取切实有效且影响深远的营运、采购、临床合作和品质倡议，以提高安全性和业务永续营运。

产业领导者应采取一系列切实有效的措施，以确保病患安全、符合监管要求，并保障药品分发营运整体的业务永续营运。首先，应优先投资于符合现行药典要求的已验证无菌製程和环境监测。这将降低注射剂製剂的风险，并支持临床给药的扩展。其次，应实施全面的供应商合格通讯协定，包括关键原料药（活性成分）的双源策略和定期供应商审核，以降低关税和供应链波动带来的风险。

我们采用高度透明的混合方法，结合与从业人员的访谈、实地评估、监管审查和资料检验，确保提供切实可行且检验的见解。

本报告的研究采用混合方法，以确保对药品分发实践、法规环境和终端用户行为获得全面且检验的见解。主要研究包括对执业兽医、配药药剂师、品质保证负责人和供应链经理进行结构化访谈，以了解实际限制和临床优先事项。此外，现场评估和流程观察直接揭示了设施布局、无菌控制和文件记录实践。

整合策略挑战，强调品质、临床协作、采购韧性和以社区为基础的永续配药运作方法。

本执行摘要了动物用药品製剂领域的核心挑战：维持严格的品质体系，根据物种和治疗方法需求调整製剂能力，以及建构能够应对关税和物流中断的弹性供应链。扩大安全注射剂和复杂製剂的范围需要完善的灭菌和文件记录流程。同时，与兽医和终端使用者进行临床合作和回馈机制对于实现治疗效果和提高用药依从性仍然至关重要，尤其是在偏好和给药方式都面临挑战的伴侣动物领域。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：兽药市场（依药物类型划分）

  • 抗感染药物
  • 抗发炎药
  • 中枢神经系统药物
  • 荷尔蒙及其替代品

第九章：兽药市场：依动物类型划分

  • 伴侣动物
    • 猫
    • 狗
    • 马
  • 家畜
    • 牛
    • 家禽
    • 绵羊/山羊
    • 猪

第十章：兽药市场：依剂型划分

  • 胶囊
  • 解决方案
  • 悬浮液

第十一章：兽药市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用

第十二章：兽药市场（依药品类型划分）

  • 非无菌配製
  • 无菌配製

第十三章：兽药市场：依通路划分

  • 离线
    • 药局
    • 兽医医院和诊所
  • 网路药房

第十四章：兽药市场：依治疗领域划分

  • 抗感染药物
  • 行为障碍
  • 循环系统
  • 皮肤科
  • 内分泌学
  • 消化系统疾病
  • 营养支持
  • 肿瘤学
  • 疼痛管理

第十五章：兽药市场：依最终用户划分

  • 动物收容所和救援组织
  • 畜牧业承诺
  • 宠物饲主
  • 兽医
  • 动物园和水族馆

第十六章：兽药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章：兽药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 兽药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国兽药市场

第二十章：中国兽药市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akina Animal Health
  • Aurora Compounding Pharmacy INC
  • Caringbah Compounding Pharmacy
  • Central Compounding Center South
  • Chiron Compounding Pharmacy, Inc
  • Custom-Med Compounding Pharmacy
  • Davis Islands Pharmacy
  • Dougherty's Pharmacy, Inc
  • Hoye's Pharmacy
  • Medisca Inc.
  • MEDS Canadian Compounding Pharmacy
  • Millers Pharmacy
  • Pace Pharmacy
  • People's Choice of Pharmacy
  • Pratt's Compounding Pharmacy
  • Sixth Avenue Medical Pharmacy
  • Smith Caldwell Drug Store by Walgreen Co.
  • Specialist Compounding Pharmacy Pte Ltd
  • Tache Pharmacy & Medical Supplies
  • Triangle Compounding Pharmacy
  • Vertisis Custom Pharmacy
  • Victoria Compounding Pharmacy
  • Vimian Group AB
  • Wedgewood Pharmacy
  • Wellness Pharmacy of Cary
Product Code: MRR-3204321AF708

The Animal Drug Compounding Market was valued at USD 1.45 billion in 2025 and is projected to grow to USD 1.57 billion in 2026, with a CAGR of 8.10%, reaching USD 2.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.57 billion
Forecast Year [2032] USD 2.51 billion
CAGR (%) 8.10%

An authoritative framing of the strategic role, scope, and practical objectives of animal drug compounding for veterinary practice and agricultural health

This executive summary begins by framing the strategic imperative of animal drug compounding in contemporary veterinary practice and agricultural management. Compounding extends the therapeutic toolbox available to veterinarians and animal health professionals by enabling dose customization, alternative formulations for small or sensitive species, and tailored combinations where approved products are not available. As a result, compounding supports clinical outcomes across acute and chronic indications, enhances medication adherence in companion animals, and provides targeted solutions for specialized livestock interventions.

The introduction clarifies the scope of inquiry, encompassing product classes, administration routes, formulation types, compounding modalities, distribution pathways, therapeutic areas and primary end users. It also situates the analysis within current regulatory expectations, quality assurance imperatives, and evolving supply chain pressures. Throughout this report, emphasis is placed on practical relevance: insights are oriented toward operational leaders, veterinary practitioners, formulary decision-makers and channel partners seeking to optimize clinical utility while maintaining compliance with sterility and safety standards.

Finally, the introduction outlines research objectives including profiling clinical demand drivers, mapping critical operational constraints, and identifying strategic priorities for stakeholders committed to improving therapeutic availability and safety for both companion and production animals. The aim is to translate technical analysis into actionable pathways for implementation and risk mitigation across compounding workflows.

How tightening regulation, supply chain volatility, and clinical demand for customized therapies are reshaping compounding operations and quality systems

Over recent years the landscape of animal drug compounding has been reshaped by several transformative shifts that touch regulation, clinical practice, and supply chain dynamics. Regulatory frameworks have tightened global expectations around sterility, labeling and batch documentation, prompting compounding operations to invest in enhanced quality systems and environmental monitoring programs. Meanwhile, clinical practice has evolved as veterinarians increasingly rely on customized formulations to manage chronic conditions, geriatric care, and species-specific dosing challenges that commercially available products do not address.

Technological diffusion has introduced more sophisticated formulation tools, automated dispensing, and digital recordkeeping that both improve traceability and create new compliance baselines. Concurrently, supply chain volatility - from API sourcing to packaging components - has encouraged compounding providers to diversify suppliers, strengthen inventory controls and pursue localized sourcing strategies where feasible. Patient- and owner-centric trends, such as demand for palatable oral solutions for cats and novel topical modalities for dermatologic conditions, have driven formulation innovation and closer collaboration between compounding pharmacists and clinicians.

Collectively, these shifts demand integrated responses: investments in sterile-processing infrastructure where injectable formulations are required, cross-functional protocols that bridge clinical needs with manufacturing capability, and quality frameworks that balance agility with robust risk controls. In short, the environment now rewards operators who can combine technical excellence with adaptive supply chain and client-centered service models.

Operational and procurement implications of U.S. tariff adjustments in 2025 on sourcing, formulation validation, and pricing dynamics across compounding operations

Tariff policies and trade measures enacted or adjusted in the United States during 2025 have a material operational impact on the compounding ecosystem, particularly where active pharmaceutical ingredients, excipients, packaging materials and specialized equipment are imported. Increased tariff burdens on specific chemical classes or finished components add cost pressure to inputs that are often sourced globally, prompting procurement teams to reassess supplier portfolios and total landed cost calculations. These effects are amplified for smaller compounding pharmacies and clinics that lack scale to absorb sudden input-price volatility.

As a consequence, many stakeholders are pivoting toward greater supplier diversification and contract renegotiation to secure more predictable access to critical materials. Some compounding operations are exploring local sourcing for certain excipients and primary packaging, while others are accelerating investments in inventory buffering and demand forecasting to mitigate the timing impact of tariff-driven lead-time changes. Regulatory compliance intersects with these adjustments because substitutions, even for non-active components, may require validation or notification depending on jurisdictional rules, which in turn influences operational agility.

In parallel, tariff-related cost shifts are nudging pricing conversations with payers and animal owners, as well as prompting greater scrutiny on formulation rationales to ensure that compounded alternatives demonstrate clear clinical necessity. For industry leaders, the tariff environment underscores the importance of integrated procurement strategies, transparent supplier qualification processes, and robust scenario planning that aligns sourcing decisions with quality and clinical imperatives.

A detailed segmentation framework connecting drug classes, species-specific needs, formulation types, administration routes, distribution channels and end-user profiles to operational priorities

A granular segmentation lens reveals where clinical need, formulation capability, and distribution overlap to create targeted opportunities and operational challenges. Based on drug type, compounding demand spans Anti-infective Agents, Anti-inflammatory Agents, CNS Agents, and Hormones & Substitutes, each of which presents distinct stability, excipient and sterility considerations. For example, hormonal preparations may require specialized handling and cold-chain awareness, while CNS agents often entail precise dose titration and careful monitoring for adverse effects.

Based on animal type, the patient pool divides into Companion Animals and Livestock. Companion Animals are further stratified into Cats, Dogs, and Horses, and each species drives unique palatability and administration preferences that influence formulation selection. Livestock further subdivides into Cattle, Poultry, Sheep & Goats, and Swine, where mass-dosing logistics, withdrawal periods and residue testing become paramount considerations for compounding strategies. Based on form, common formats include Capsules, Solutions, and Suspensions, and the choice of form affects adherence, dosing accuracy and stability profiles.

Based on route of administration, Injectable, Oral, and Topical pathways demand different sterility controls, packaging and administration training for end users. Based on compounding type, operations distinguish between Non-Sterile Compounding and Sterile Compounding, driving divergent infrastructure needs, from laminar-flow hoods to validated cleanroom suites. Based on distribution channel, the ecosystem includes Offline and Online Pharmacies, with Offline further segmented into Compounding Pharmacies and Veterinary Hospitals & Clinics; these channels influence turnaround time expectations, client interaction models and returns management. Based on therapeutic area, compounding addresses Anti-Infectives, Behavioral Disorders, Cardiology, Dermatology, Endocrinology, Gastrointestinal Disorders, Nutritional Support, Oncology, and Pain Management, each requiring tailored clinical protocols. Finally, based on end user, primary recipients include Animal Shelters & Rescues, Livestock Farmers, Pet Owners, Veterinarians, and Zoological Institutions, and each end user profile shapes procurement rhythm, formulation preferences and documentation needs.

This segmentation-driven perspective clarifies where investment in specific capabilities-such as sterile processing for injectable oncology adjuncts, palatable suspension development for feline patients, or scalable oral solutions for herd treatment-will deliver the greatest clinical and commercial return. It also highlights the importance of aligning quality management, supply continuity, and distribution models to the specific demands of each segment.

How regional regulatory diversity, supply chain roles, and adoption patterns in the Americas, EMEA and Asia-Pacific shape compounding strategies and operational risk

Regional dynamics continue to define regulatory expectations, sourcing strategies and adoption patterns across the compounding landscape. In the Americas, regulatory frameworks emphasize traceability, sterility assurance and transparency of compounding records, while commercial adoption is shaped by a dense ecosystem of veterinary clinics and specialty compounding pharmacies that serve both companion animals and large farming operations. This regional configuration supports rapid clinical feedback loops but also concentrates regulatory scrutiny on compounding practices and documentation.

In Europe, Middle East & Africa, heterogeneous regulatory environments require nuanced compliance strategies and localized quality controls, with some markets imposing stringent pharmacopoeial adherence and others prioritizing access in veterinary public health contexts. Distribution modalities in this macro-region vary widely, and cross-border supply chains often necessitate harmonized labeling and stability data that satisfy multiple jurisdictions. Asia-Pacific exhibits dynamic demand drivers, with rapid growth in companion animal ownership in urban centers and continuing modernization of livestock practices. The region also plays a meaningful role in the global supply chain for APIs and primary packaging, which creates both opportunity and exposure to upstream manufacturing variation.

Across all regions, differences in veterinary infrastructure, cold-chain capabilities, and professional training affect the feasibility of certain compounded therapies. Consequently, regional strategies must reconcile local regulatory requirements, supply chain realities and clinical practice norms to ensure that compounding services remain safe, accessible and operationally sustainable.

Strategic priorities and operational differentiators among compounding providers focused on quality infrastructure, clinical integration, and resilient supply chains

Companies operating in the animal drug compounding space are converging around several strategic imperatives that differentiate performance and resilience. Leading compounding pharmacies and service providers are prioritizing quality infrastructure investments, including validated cleanrooms, environmental monitoring systems and rigorous sterility testing protocols, to meet heightened regulatory expectations and to enable growth into injectable and biologic-adjacent formulations. Parallel to facility upgrades, firms are formalizing compliance programs with standardized batch records, electronic traceability and routine third-party audits.

Commercially, innovators are developing integrated service models that combine rapid-turnaround compounding with clinical consultation, training for administration by veterinarians or farm personnel, and digital platforms for prescription management. Partnerships between compounding producers and veterinary hospital networks enable tighter clinical feedback loops, accelerating iterative improvements in palatability, dosing accuracy and ease of administration. On the supply side, companies are investing in supplier qualification processes, dual-sourcing arrangements for critical APIs and localized inventories to reduce exposure to international logistical disruptions.

Additionally, some organizations are pursuing research collaborations to validate stability profiles and to expand the evidence base for compounded therapies in specific species and therapeutic contexts. Talent and capability building-across sterile processing technicians, veterinary pharmacists and regulatory specialists-remains a key differentiator. Collectively, these company-level strategies reveal a competitive landscape where compliance excellence, clinical integration and supply chain agility determine sustainable value creation.

Practical, high-impact operational, procurement, clinical collaboration, and quality actions for compounding leaders to strengthen safety and business continuity

Industry leaders should adopt a set of pragmatic, high-impact actions to safeguard patient safety, regulatory compliance and commercial continuity across compounding operations. First, prioritize investments in validated aseptic processing and environmental monitoring that align with current pharmacopeial expectations; this reduces risk exposure for injectable formulations and supports expanded clinical offerings. Next, implement comprehensive supplier qualification protocols, including dual-source strategies for critical APIs and periodic supplier audits, to mitigate tariff and supply chain volatility.

Simultaneously, strengthen clinical collaboration by formalizing feedback mechanisms with veterinarians and end users to refine palatability, dosing formats and administration training. Design digital prescription and fulfillment workflows that increase traceability while also improving turnaround times for practitioners. Where feasible, standardize stability and validation studies for frequently compounded formulations to limit ad hoc substitutions and to improve consistency across batches. Complement technical measures with workforce development programs that elevate competence in sterile technique, compounding documentation and regulatory reporting.

Finally, incorporate scenario-based procurement planning that explicitly models tariff and logistics contingencies, and develop transparent pricing rationales that can be communicated to clients when input costs fluctuate. Taken together, these steps create a defensible operational posture that balances clinical responsiveness with robust quality controls and commercial transparency.

A transparent mixed-methods research approach combining practitioner interviews, site assessments, regulatory review and data triangulation to ensure practical and verifiable insights

The research underpinning this report used a mixed-methods approach to ensure comprehensive, verifiable insights into compounding operations, regulatory context, and end-user behavior. Primary research included structured interviews with practicing veterinarians, compounding pharmacists, quality assurance professionals and supply chain managers to capture real-world operational constraints and clinical priorities. In addition, site assessments and process observations provided direct visibility into facility layout, sterile processing controls and documentation practices.

Secondary research involved systematic review of regulatory guidance, pharmacopeial standards, and publicly available clinical literature to validate technical assertions on stability, sterility and therapeutic rationale for compounded preparations. Data triangulation combined qualitative inputs with operational indicators from industry reports, procurement trends and supplier intelligence to produce robust thematic conclusions. Analytical frameworks included segmentation analysis across drug type, animal species, formulation, route of administration, compounding modality, distribution channel, therapeutic area and end-user cohort.

Limitations of the methodology are acknowledged; availability of proprietary operational metrics varied across respondents, and regulatory interpretations differ by jurisdiction which may affect local implementation. Where differences emerged, the analysis highlights variance and suggests decision points for stakeholders. Overall, the methodology emphasizes reproducibility, transparency and practical relevance for clinical and commercial leaders.

Synthesis of strategic imperatives emphasizing quality, clinical collaboration, procurement resilience and regionally adapted approaches for sustainable compounding operations

This executive summary synthesizes core imperatives for the animal drug compounding sector: maintain uncompromising quality systems, align formulation capabilities with species- and therapy-specific needs, and build resilient supply chains that can absorb tariff and logistics disruption. Operational preparedness in sterile processing and documentation is essential to broaden the range of safe injectable and complex formulations. Meanwhile, clinical collaboration and feedback loops with veterinarians and end users remain central to achieving therapeutic efficacy and adherence, particularly for companion animals with heightened palatability and dosing challenges.

Procurement strategies that emphasize supplier qualification, inventory stewardship and scenario planning provide a pragmatic buffer against input volatility. Regionally differentiated approaches are necessary because regulatory frameworks, vet infrastructure, and supply chain roles vary significantly across the Americas, EMEA and Asia-Pacific. Companies that integrate technical excellence with flexible commercial models and targeted workforce development will be best positioned to deliver clinically meaningful compounded therapies while meeting evolving compliance expectations.

In closing, sustained focus on quality, clinical integration and supply chain intelligence will enable compounding operations to respond responsibly to both everyday veterinary needs and emergent therapeutic demands, preserving patient safety and supporting long-term operational viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Drug Compounding Market, by Drug Type

  • 8.1. Anti-infective Agents
  • 8.2. Anti-inflammatory Agents
  • 8.3. CNS Agents
  • 8.4. Hormones & Substitutes

9. Animal Drug Compounding Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
    • 9.1.3. Horses
  • 9.2. Livestock
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep & Goats
    • 9.2.4. Swine

10. Animal Drug Compounding Market, by Form

  • 10.1. Capsules
  • 10.2. Solutions
  • 10.3. Suspensions

11. Animal Drug Compounding Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Topical

12. Animal Drug Compounding Market, by Compounding Type

  • 12.1. Non-Sterile Compounding
  • 12.2. Sterile Compounding

13. Animal Drug Compounding Market, by Distribution Channel

  • 13.1. Offline
    • 13.1.1. Compounding Pharmacies
    • 13.1.2. Veterinary Hospitals & Clinics
  • 13.2. Online Pharmacies

14. Animal Drug Compounding Market, by Therapeutic Area

  • 14.1. Anti-Infectives
  • 14.2. Behavioral Disorders
  • 14.3. Cardiology
  • 14.4. Dermatology
  • 14.5. Endocrinolog
  • 14.6. Gastrointestinal Disorders
  • 14.7. Nutritional Support
  • 14.8. Oncology
  • 14.9. Pain Management

15. Animal Drug Compounding Market, by End User

  • 15.1. Animal Shelters & Rescues
  • 15.2. Livestock Farmers
  • 15.3. Pet Owners
  • 15.4. Veterinarians
  • 15.5. Zoological Institutions

16. Animal Drug Compounding Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Animal Drug Compounding Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Animal Drug Compounding Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Animal Drug Compounding Market

20. China Animal Drug Compounding Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Akina Animal Health
  • 21.6. Aurora Compounding Pharmacy INC
  • 21.7. Caringbah Compounding Pharmacy
  • 21.8. Central Compounding Center South
  • 21.9. Chiron Compounding Pharmacy, Inc
  • 21.10. Custom-Med Compounding Pharmacy
  • 21.11. Davis Islands Pharmacy
  • 21.12. Dougherty's Pharmacy, Inc
  • 21.13. Hoye's Pharmacy
  • 21.14. Medisca Inc.
  • 21.15. MEDS Canadian Compounding Pharmacy
  • 21.16. Millers Pharmacy
  • 21.17. Pace Pharmacy
  • 21.18. People's Choice of Pharmacy
  • 21.19. Pratt's Compounding Pharmacy
  • 21.20. Sixth Avenue Medical Pharmacy
  • 21.21. Smith Caldwell Drug Store by Walgreen Co.
  • 21.22. Specialist Compounding Pharmacy Pte Ltd
  • 21.23. Tache Pharmacy & Medical Supplies
  • 21.24. Triangle Compounding Pharmacy
  • 21.25. Vertisis Custom Pharmacy
  • 21.26. Victoria Compounding Pharmacy
  • 21.27. Vimian Group AB
  • 21.28. Wedgewood Pharmacy
  • 21.29. Wellness Pharmacy of Cary

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL DRUG COMPOUNDING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CNS AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CNS AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CNS AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORMONES & SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORMONES & SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORMONES & SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NON-STERILE COMPOUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NON-STERILE COMPOUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NON-STERILE COMPOUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY STERILE COMPOUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY STERILE COMPOUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY STERILE COMPOUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ENDOCRINOLOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ENDOCRINOLOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ENDOCRINOLOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL SHELTERS & RESCUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL SHELTERS & RESCUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL SHELTERS & RESCUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK FARMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK FARMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARIANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARIANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARIANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ZOOLOGICAL INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ZOOLOGICAL INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ZOOLOGICAL INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 246. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 282. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 293. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 294. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA ANIMAL DRU